Novarex KRX:194700KOSDAQ
노바렉스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Novarex reported revenue of ₩102bn, up 2.7% year on year, and operating profit of ₩11.0bn. Novarex (노바렉스) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 28 with 1 article. It was most often mentioned alongside Neo Cremar and Suheung.
Novarex quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩102bn | +2.7% | ₩11.0bn margin 10.8% | ₩7.7bn |
| Q1 2026 | ₩121bn | +33.2% | ₩14.1bn margin 11.7% | ₩14.9bn |
| Q4 2025 derived | ₩101bn | +22.5% | ₩10.7bn margin 10.6% | ₩8.5bn |
| Q3 2025 | ₩114bn | +47.3% | ₩12.9bn margin 11.3% | ₩12.4bn |
| Q2 2025 | ₩99.1bn | +21.2% | ₩11.0bn margin 11.1% | ₩7.8bn |
| Q1 2025 | ₩90.7bn | +60.4% | ₩8.4bn margin 9.3% | ₩7.2bn |
| Q4 2024 derived | ₩82.2bn | +7.5% | ₩6.7bn margin 8.2% | ₩9.4bn |
| Q3 2024 | ₩77.3bn | -4.0% | ₩5.5bn margin 7.2% | ₩3.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Novarex top stories 2 weeks, by number of outlets
- 1